Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures
Cosmo Pharmaceuticals has announced the publication of a landmark study in The Lancet, demonstrating the efficacy of their GI Genius™ intelligent endoscopy system in colonoscopy procedures. The COLO-DETECT study, a multicentre, open-label, randomised controlled trial, showed that GI Genius™ improved the detection of colorectal adenomas in an additional 8.3% of patients compared to standard colonoscopy practices.
This significant advancement in colorectal cancer screening could potentially reduce cancer incidence. The study reinforces the value of integrating AI into routine clinical practice for enhanced accuracy in cancer screening. Cosmo Pharmaceuticals, in partnership with Medtronic for global distribution, remains committed to advancing patient care through AI-assisted healthcare technology.
Cosmo Pharmaceuticals ha annunciato la pubblicazione di uno studio fondamentale in The Lancet, che dimostra l'efficacia del loro sistema di endoscopia intelligente GI Genius™ nelle procedure di colonoscopia. Lo studio COLO-DETECT, uno studio multicentrico, in aperto e controllato randomizzato, ha mostrato che GI Genius™ ha migliorato la rilevazione degli adenomi colorettali in un ulteriore 8,3% dei pazienti rispetto alle pratiche standard di colonoscopia.
Questo importante progresso nella screening del cancro colorettale potrebbe potenzialmente ridurre l'incidenza del cancro. Lo studio rafforza il valore dell'integrazione dell'IA nella pratica clinica di routine per una maggiore precisione nello screening del cancro. Cosmo Pharmaceuticals, in collaborazione con Medtronic per la distribuzione globale, rimane impegnata a migliorare la cura dei pazienti attraverso la tecnologia sanitaria assistita dall'IA.
Cosmo Pharmaceuticals ha anunciado la publicación de un estudio pionero en The Lancet, que demuestra la eficacia de su sistema de endoscopia inteligente GI Genius™ en procedimientos de colonoscopia. El estudio COLO-DETECT, un ensayo controlado aleatorio multicéntrico, mostró que GI Genius™ mejoró la detección de adenomas colorrectales en un 8,3% adicional de pacientes en comparación con las prácticas estándar de colonoscopia.
Este avance significativo en la detección del cáncer colorrectal podría reducir potencialmente la incidencia del cáncer. El estudio refuerza el valor de integrar la IA en la práctica clínica rutinaria para una mayor precisión en la detección del cáncer. Cosmo Pharmaceuticals, en asociación con Medtronic para la distribución global, sigue comprometida con mejorar la atención al paciente a través de la tecnología de salud asistida por IA.
Cosmo Pharmaceuticals는 The Lancet에 발표된 기념비적인 연구 결과를 발표했습니다. 이 연구는 GI Genius™ 지능형 내시경 시스템이 대장내시경 절차에서의 효능을 입증했습니다. COLO-DETECT 연구는 다기관 공개라벨 무작위 대조시험으로, GI Genius™가 표준 대장내시경 절차에 비해 환자의 8.3%에서 대장 폴립 발견율을 개선했다고 합니다.
이러한 대장암 검진의 중요한 진전은 암 발생률을 줄일 수 있는 가능성을 가지고 있습니다. 이 연구는 암 스크리닝의 정확성을 높이기 위해 일상적인 임상 실습에 AI를 통합하는 것의 가치를 강화합니다. Cosmo Pharmaceuticals는 전 세계 배급을 위해 Medtronic과 협력하여 환자 치료를 AI 지원 건강 기술을 통해 개선하는 데 전념하고 있습니다.
Cosmo Pharmaceuticals a annoncé la publication d'une étude décisive dans The Lancet, démontrant l'efficacité de leur système d'endoscopie intelligent GI Genius™ lors des procédures de coloscopie. L'étude COLO-DETECT, un essai contrôlé randomisé multicentrique, a montré que GI Genius™ améliorait la détection des adénomes colorectaux chez un 8,3 % supplémentaire de patients par rapport aux pratiques standard de coloscopie.
Cette avancée significative dans le dépistage du cancer colorectal pourrait potentiellement réduire l'incidence du cancer. L'étude renforce la valeur de l'intégration de l'IA dans la pratique clinique courante pour une meilleure précision dans le dépistage du cancer. Cosmo Pharmaceuticals, en partenariat avec Medtronic pour la distribution mondiale, reste engagée à améliorer les soins aux patients grâce à la technologie de santé assistée par IA.
Cosmo Pharmaceuticals hat die Veröffentlichung einer wegweisenden Studie in The Lancet angekündigt, die die Wirksamkeit ihres intelligenten Endoskopiesystems GI Genius™ bei Koloskopieverfahren nachweist. Die Studie COLO-DETECT, eine multizentrische, offene, randomisierte kontrollierte Studie, zeigte, dass GI Genius™ die Erkennung von kolorektalen Adenomen bei 8,3% zusätzlicher Patienten im Vergleich zu den Standardverfahren der Koloskopie verbesserte.
Dieser bedeutende Fortschritt bei der Früherkennung von Kolorektalkrebs könnte potenziell die Krebsinzidenz reduzieren. Die Studie unterstreicht den Wert der Integration von KI in die routinemäßige klinische Praxis zur Verbesserung der Genauigkeit bei der Krebsfrüherkennung. Cosmo Pharmaceuticals, in Partnerschaft mit Medtronic für den weltweiten Vertrieb, bleibt verpflichtet, die Patientenversorgung durch KI-unterstützte Gesundheitstechnologie voranzubringen.
- Publication of landmark study in prestigious medical journal The Lancet
- GI Genius™ system improved colorectal adenoma detection by 8.3% compared to standard colonoscopy
- Potential reduction in colorectal cancer incidence through improved polyp detection
- Reinforces the value of AI integration in routine clinical practice
- Global distribution partnership with Medtronic for wider accessibility
- None.
Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a landmark study in “The Lancet”. This study, titled “Polyp detection with colonoscopy assisted by the GI Genius™ artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, randomised controlled trial”, represents a significant advancement in colorectal cancer screening and detection.
The COLO-DETECT study, conducted by a team of researchers including Alexander Seager, MSc, Prof. Linda Sharp, PhD, and Laura J. Neilson, MD, among others, provides evidence supporting the effectiveness of the GI Genius™ system in enhancing polyp detection rates during colonoscopy. This multicentre, open-label trial demonstrated that the use of GI Genius™ improves the detection of colorectal adenomas in an additional
“This publication is a major milestone not only for Cosmo Pharmaceuticals but also for the global medical community,” said Gio Di Napoli, CEO of Cosmo Pharmaceuticals. “The GI Genius™ system, exclusively distributed by Medtronic globally, continues to prove its value in routine clinical practice, by assisting in providing better outcomes for patients undergoing colonoscopy. We are proud to be at the forefront of innovation in AI-assisted healthcare, and this study reinforces our commitment to advancing patient care through cutting-edge technology.”
The study’s results demonstrate the value of integrating AI into routine clinical practice to enhance the accuracy and effectiveness of colorectal cancer screening. With colorectal cancer being one of the leading causes of cancer-related deaths worldwide, the improved detection of precancerous polyps is critical for early intervention and prevention.
Cosmo Pharmaceuticals remains committed to supporting the medical community with innovative solutions like GI Genius™, which exemplify the future of AI in healthcare. The Company will continue working closely with its distribution partner, Medtronic, to ensure this life-saving technology is accessible to healthcare providers globally.
For more information about the study and the GI Genius™ system, please visit https://www.thelancet.com and https://www.cosmopharma.com respectively.
About Cosmo
Cosmo is a pharmaceutical company focused on developing and commercializing products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions, and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda®/Mezavant®/Mesavancol®, Uceris®/Cortiment®, Aemcolo®/ Relafalk®, Lumeblue®, and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. The Company also has a rich development pipeline. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com.
Upcoming Calendar of Events
H.C. Wainwright Global Investment Conference, N.Y. September 9-11, 2024
UBS Global Healthcare Conference, California November 11-14, 2024
For further information, please contact
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Attachments
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221851
FAQ
What is the main finding of the COLO-DETECT study for Cosmo Pharmaceuticals (CMOPF)?
Where was the COLO-DETECT study for Cosmo Pharmaceuticals (CMOPF) published?
How does the GI Genius™ system by Cosmo Pharmaceuticals (CMOPF) potentially impact colorectal cancer?
Who is the distribution partner for Cosmo Pharmaceuticals' (CMOPF) GI Genius™ system?
